Exact Mass: 401.16857319999997
Exact Mass Matches: 401.16857319999997
Found 93 metabolites which its exact mass value is equals to given mass value 401.16857319999997,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Moxifloxacin
Moxifloxacin is only found in individuals that have used or taken this drug. It is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.The bactericidal action of moxifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01M - Quinolone antibacterials > J01MA - Fluoroquinolones D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AE - Fluoroquinolones D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic D004791 - Enzyme Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
N-[4-[1-[2-(6-Methylpyridin-2-yl)ethyl]piperidine-4-carbonyl]phenyl]methanesulfonamide
C21H27N3O3S (401.1773032000001)
D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
2-(1-carboxy-2-hydroxypropyl)-4-{[5-(dimethylcarbamoyl)pyrrolidin-3-yl]sulfanyl}-3-methyl-3,4-dihydro-2h-pyrrole-5-carboxylic acid
3-Quinolinecarboxylic acid, 7-((3R)-3-(1-aminocyclopropyl)-1-pyrrolidinyl)-1-((1R,2S)-2-fluorocyclopropyl)-1,4-dihydro-8-methoxy-4-oxo-
Ghrelin agonist HM01
E-4031
C21H27N3O3S (401.1773032000001)
D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
Moxifloxacin
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01M - Quinolone antibacterials > J01MA - Fluoroquinolones D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors S - Sensory organs > S01 - Ophthalmologicals > S01A - Antiinfectives > S01AE - Fluoroquinolones D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C254 - Anti-Infective Agent > C258 - Antibiotic > C795 - Quinolone Antibiotic D004791 - Enzyme Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Meropenem Metabolite (2H-Pyrrole-2-acetic acid, 5-carboxy-4-[[(3S,5S)-5-[(dimethylamino)carbonyl]-3-
3-(9H-fluoren-9-ylmethoxycarbonylamino)-3-(4-methylphenyl)propanoic acid
C25H23NO4 (401.16269980000004)
N-Fmoc-erythro-DL-beta-methylphenylalanine
C25H23NO4 (401.16269980000004)
fmoc-(r)-3-amino-3-(2-methyl-phenyl)-propionic acid
C25H23NO4 (401.16269980000004)
fmoc-(r)-3-amino-3-(3-methyl-phenyl)-propionic acid
C25H23NO4 (401.16269980000004)
[2-[(2-Aminophenyl)thio]phenyl][4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]methanone
C21H27N3O3S (401.1773032000001)
Fmoc-4-(4-aminophenyl)butanoic acid
C25H23NO4 (401.16269980000004)
fmoc-(s)-3-amino-3-(3-methyl-phenyl)-propionic acid
C25H23NO4 (401.16269980000004)
3-(9 H-FLUOREN-9-YLMETHOXYCARBONYLAMINO)-4-PHENYL-BUTYRIC ACID
C25H23NO4 (401.16269980000004)
TNP 470
C19H28ClNO6 (401.16050580000007)
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C2143 - Endothelial Cell Inhibitor D006133 - Growth Substances > D043924 - Angiogenesis Modulating Agents D000970 - Antineoplastic Agents > D020533 - Angiogenesis Inhibitors D006133 - Growth Substances > D006131 - Growth Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
(R)-3-((((9H-FLUOREN-9-YL)METHOXY)CARBONYL)AMINO)-2-BENZYLPROPANOIC ACID
C25H23NO4 (401.16269980000004)
(4R,5S)-5-[(1S,2R)-1-Carboxy-2-hydroxypropyl]-3-{[(3S,5S)-5-(dimethylcarbamoyl)-3-pyrrolidinyl]sulfanyl}-4-methyl-4,5-dihydro-1H-pyrrole-2-carboxylic acid
1-cyclopropyl-6-fluoro-1,4-dihydro-7-((4aR,7aS)-octahydropyrrolo [3,4-b]pyridin-6-yl)-8-Methoxy-4-oxoquinoline-3-carboxylic acid
Copper(2+) bis[3-(3-ethylcyclopentyl)propanoate]
C20H34CuO4 (401.17529540000004)
fmoc-(s)-3-amino-3-(4-methyl-phenyl)-propionic acid
C25H23NO4 (401.16269980000004)
fmoc-(s)-3-amino-3-(2-methyl-phenyl)-propionic acid
C25H23NO4 (401.16269980000004)
fmoc-(r)-3-amino-3-(4-methyl-phenyl)-propionic acid
C25H23NO4 (401.16269980000004)
N-(4-{[2-(diphenylacetyl)hydrazino]carbonyl}phenyl)propanamide
6,7-Dimethoxy-4-[(3r)-3-(2-Naphthyloxy)pyrrolidin-1-Yl]quinazoline
N-[5-ethyl-3-[(4-methoxyphenyl)-oxomethyl]-2-thiophenyl]-2-(4-methyl-1-piperazinyl)acetamide
C21H27N3O3S (401.1773032000001)
N-[3-(6-Phenyl-3H-imidazo[4,5-b]pyridine-2-yl)-4-fluorophenyl]pyrrolidine-1-carboxamide
4-fluoro-N-[4-[[[2-(methylamino)-4-quinazolinyl]amino]methyl]phenyl]benzamide
ethyl N-[4-[(4,4-diethyl-2,5-dioxoimidazolidin-1-yl)methyl]-2-oxochromen-7-yl]carbamate
1-[(5,8-dimethyl-2-oxo-1H-quinolin-3-yl)methyl]-1-(2-furanylmethyl)-3-phenylurea
3-[[4-(2,3-dimethylphenyl)-1-piperazinyl]-oxomethyl]-N,N-dimethylbenzenesulfonamide
C21H27N3O3S (401.1773032000001)
(1R,5S)-7-[4-[(E)-prop-1-enyl]phenyl]-N-[4-(trifluoromethyl)phenyl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxamide
N-[(2S,3R,6R)-6-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide
N-[(2S,3S,6S)-6-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide
N-[(2S,3S,6R)-6-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide
N-[(2S,3R,6S)-6-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide
N-[(2R,3S,6R)-6-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide
N-[(2R,3S,6S)-6-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide
N-[(2R,3R,6R)-6-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide
N-[(2R,3R,6S)-6-[2-[(3-fluorophenyl)methylamino]-2-oxoethyl]-2-(hydroxymethyl)-3-oxanyl]-2-pyridinecarboxamide
(1S,5R)-7-[4-[(E)-prop-1-enyl]phenyl]-N-[4-(trifluoromethyl)phenyl]-3,6-diazabicyclo[3.1.1]heptane-6-carboxamide
N-Fmoc-N-benzyl-L-alanine
C25H23NO4 (401.16269980000004)
N-(((9H-Fluoren-9-yl)methoxy)carbonyl)-N-benzyl-L-alanine is an alanine derivative[1].
SHEN26
SHEN26 (ATY014) is a potent and orally active RdRp inhibitor, with an IC50 for SARS-CoV-2 is 1.36 μM. SHEN26 is a 5’-cyclohexanecarboxylate derivative of GS-441524 (HY-103586). SHEN26 inhibits viral nucleic acid synthesis to achieve antiviral effects. SHEN26 can be used for the research of coronavirus disease 2019 (COVID-19)[1][2].
Sonepiprazole
C21H27N3O3S (401.1773032000001)
Sonepiprazole (PNU-101387G) is a selective D4 dopamine antagonist with Kis of 3.6, 10.1, 5147, and 7430 nM for rD4-Dopamine, hD4.2-Dopamine, rD2-Dopamine, and Histamine-H1 receptors, respectively[1].
(3r,4s,5s,6r)-5-methoxy-4-[(3r)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl n-(2-chloro-1-hydroxyethylidene)carbamate
C19H28ClNO6 (401.16050580000007)
(2r,10s,12s)-13-hydroxy-10-(2-methylbut-3-en-2-yl)-21-oxo-1,3,14-triazapentacyclo[10.9.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]henicosa-4,6,8,13,15,17,19-heptaene-3-carbaldehyde
5-methoxy-4-[2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl n-(2-chloro-1-hydroxyethylidene)carbamate
C19H28ClNO6 (401.16050580000007)